Biosimilars in Dermatology Review.

J Psoriasis Psoriatic Arthritis

Dermatology Department, University at Buffalo, Buffalo, NY, USA.

Published: January 2024

AI Article Synopsis

  • Biosimilars, like infliximab and rituximab, can enhance access to effective medications, with new versions of adalimumab expected in 2023.
  • This review examines the basics of biosimilars and their use in dermatology across the US, Asia, and Europe, based on extensive literature from 2015 to early 2023.
  • Although biosimilars have achieved significant savings and market share growth in Europe, the same success has not yet been mirrored in the US, highlighting the need for better prescribing incentives and physician education.

Article Abstract

Background: Safe and effective biosimilar medications have the potential to significantly increase access to these valuable drugs. The two current biosimilars available in dermatology in the United States (US) are infliximab and rituximab which were Food and Drug Administration (FDA) approved in 2016 and 2018 respectively. There has been significant interest in this topic as a number of biosimilar versions of adalimumab will be available in 2023.

Objective: This review will discuss biosimilar basics and the experience with biosimilars used in dermatology in the US, Asia, and Europe.

Methods: All articles in Ovid/Medline from 2015 to Feb 2023 on biosimilars were reviewed with a particular emphasis on medications used in dermatology. Other reports from pharmaceutical manufacturers and blogs following the development of the biosimilar industry provided key insights.

Results: Biosimilars have been able to produce significant savings and market share increases, particularly in Europe, where there has been a longer experience. The specifics depend on drug prescribing practices and incentives in the individual country. This degree of savings and market share increases have not been realized with the current biosimilars available in the US.

Conclusion: While biosimilars have resulted in significant savings compared to originator drugs, it is clear that prescribing incentives and physician education are crucial in achieving these savings. To what degree biosimilar market share will increase in the US remains to be determined.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361486PMC
http://dx.doi.org/10.1177/24755303231212154DOI Listing

Publication Analysis

Top Keywords

biosimilars dermatology
12
market share
12
current biosimilars
8
savings market
8
share increases
8
biosimilars
7
biosimilar
5
dermatology review
4
review background
4
background safe
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!